NASDAQ · NAMS
NewAmsterdam Pharma Company N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NAMS: Nov 4, 2026
NewAmsterdam Pharma Company N.V. Ordinary Shares is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.5. The reported EPS for the same quarter last year was $-0.41.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.50 | $-0.35 | $-0.62 | 5 |
| Dec 2026 | $-0.38 | $-0.27 | $-0.53 | 5 |
| Mar 2027 | $-0.57 | $-0.53 | $-0.62 | 2 |
| Jun 2027 | $-0.61 | $-0.55 | $-0.66 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat · BNK Invest- RTTNews · Sep 21, 10:44 AM EDTNewAmsterdam Wins First Global Approval For Obicetrapib Cholesteorl Treatments(RTTNews) – NewAmsterdam Pharma (NAMS) and its commercial partner Menarini Group said the European Commission has granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (a fixed-dose combination of obicetrapib and ezetimibe) for adults with primary hyper
- Zacks · Sep 15, 8:47 AM EDTAclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- MarketBeat · Aug 5, 1:04 PM EDTNewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim NearsNewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch. Chief Executive Officer Micha
- Zacks · Aug 5, 9:55 AM EDTNewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue EstimatesNewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 27, 3:40 AM EDTNewAmsterdam, Menarini Secure Positive CHMP Opinion For Obicetrapib & Evlarco To Treat Cholesterol(RTTNews) – NewAmsterdam Pharma Company N.V. (NAMS), a late-stage clinical biopharmaceutical company and partner Menarini Group, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending m
- MarketBeat · May 8, 2:06 AM EDTNewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded TrendsNewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in two-year blinded data and a lower-th
- Zacks · May 7, 8:50 AM EDTNewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesNewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +13.66% and +35.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- BNK Invest · Feb 23, 10:40 AM ESTInteresting NAMS Put And Call Options For July 17thInvestors in NewAmsterdam Pharma Company N V (Symbol: NAMS) saw new options become available this week, for the July 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 144 days until expiration the
- BNK Invest · Jan 16, 11:39 AM ESTFirst Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS)Investors in NewAmsterdam Pharma Company N V (Symbol: NAMS) saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NAMS options chain for the new March 20th contracts and identified
- BNK Invest · Jan 15, 12:04 PM ESTRelative Strength Alert For NewAmsterdam Pharma CompanyLegendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Fintel · Dec 16, 7:05 PM ESTStifel Maintains NewAmsterdam Pharma Company N.V. (NAMS) Buy RecommendationFintel reports that on December 16, 2025, Stifel maintained coverage of NewAmsterdam Pharma Company N.V. (NasdaqGM:NAMS) with a Buy recommendation. Analyst Price Forecast Suggests 40.59% Upside
- Fintel · Dec 2, 5:48 PM ESTGoldman Sachs Maintains NewAmsterdam Pharma Company N.V. (NAMS) Neutral RecommendationFintel reports that on December 2, 2025, Goldman Sachs maintained coverage of NewAmsterdam Pharma Company N.V. (NasdaqGM:NAMS) with a Neutral recommendation. Analyst Price Forecast Suggests 20.04% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for NewAmsterdam Pharma Company N.V. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.